Funded Biotechnology Startups in La Jolla
Across the 18 most recent La Jolla biotechnology rounds shown, the largest disclosed raise is Inhibrx at $150M on 2025-01-13; it stands out against the res…
Across the 18 most recent La Jolla biotechnology rounds shown, the largest disclosed raise is Inhibrx at $150M on 2025-01-13; it stands out against the rest of the disclosed amounts, where most are below that level and the next-largest disclosed amounts are $350M (Janux Therapeutics, 2024-12-03) and $150M also appears again with Kura Oncology (2024-01-24). At the same time, “undisclosed” appears once (Tentarix Biotherapeutics on 2023-08-15), while a large share of entries are tagged Series Unknown (9 of 18).
The date window spans 2020-09-21 (Dare Bioscience, $900K) through 2026-06-24 (CalciMedica, $49M), and several rounds cluster tightly in 2024–2025: for example, Janux Therapeutics ($350M, 2024-12-03), INmuneBIO ($13M, 2024-09-13), Equillium ($35M, 2026-03-13) and Artelo Biosciences ($11M, 2026-03-27) bracket a period where disclosed checks range from single-digit millions to $350M. One clear outlier on the low end is Dare Bioscience’s $900K in 2020, far below other disclosed rounds such as MatriSys Bioscience’s $3M (2021-03-11) and most of the 2021–2024 disclosed amounts that sit in the tens of millions.
Most recent rounds
18 shownRelated listings
Frequently asked
What’s the largest disclosed biotech round in this La Jolla list, and how does it compare to the rest?
The largest disclosed round is Janux Therapeutics at $350M (2024-12-03). The next-largest disclosed amounts include $150M for Inhibrx (2025-01-13) and $150M for Kura Oncology (2024-01-24), while most other disclosed rounds fall well below those levels.
Do the rounds cluster in time, or are they evenly spread across the displayed window?
They’re not evenly spread: the list runs from 2020-09-21 (Dare Bioscience, $900K) to 2026-06-24 (CalciMedica, $49M), with multiple high-value disclosed rounds concentrated in 2024–2025. Examples include Janux Therapeutics ($350M, 2024-12-03), Kura Oncology ($150M, 2024-01-24), and Equillium ($35M, 2026-03-13) and Artelo Biosciences ($11M, 2026-03-27) landing in consecutive quarters.
Are any stages over-represented in this dataset?
Series Unknown accounts for 9 of the 18 rows (including CalciMedica 2026-06-24 at $49M, Artelo Biosciences 2026-03-27 at $11M, and Equillium 2026-03-13 at $35M). The rest are distributed across named stages such as Series B (e.g., Genome Insight $23M on 2023-11-01; Singlera Genomics $45M on 2022-06-08) and Series A (Rampart Bioscience $85M on 2023-10-24).
Is there a low-end outlier worth flagging for diligence or benchmarking?
Yes. Dare Bioscience’s $900K round (2020-09-21) is the smallest disclosed amount shown and is much lower than the next smallest disclosed entry, MatriSys Bioscience at $3M (2021-03-11). Most other disclosed rounds cluster in the millions-to-hundreds-of-millions range (e.g., INmuneBIO $13M on 2024-09-13; PetDx $62M on 2021-12-09).
How should buyers interpret undisclosed and missing stage signals here?
Stage and amount completeness vary: 9 of 18 rows are labeled Series Unknown, and one row has an undisclosed amount (Tentarix Biotherapeutics on 2023-08-15). That means comparisons by “largest round” should be limited to disclosed amounts when evaluating companies like Janux Therapeutics ($350M) versus Tentarix’s undisclosed check.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.